Johnson & Johnson Innovation: Battling Chronic Kidney Disease (CKD)
BackSep 28, 2021 10:15 am - 11:45 am PT
About 37 million Americans adults have Chronic Kidney Disease (CKD) and millions more are at an increased risk*. As we gain greater understanding of kidney disease pathophysiology, we anticipate developing more effective therapeutics and tools for prevention and treatment.
In this webinar, our panel of scientific experts and entrepreneurs will discuss the latest science and new areas of discovery they feel are primed to help overcome the current challenges of CKD.
We will cover some specific topics including:
– Strategies to stop the progression and reverse the sequence of the disease
– New insights into pathways or mechanisms for kidney repair from novel technologies
– Challenges and opportunities on new therapeutic modalities for CKD, e.g. siRNA, protein degraders, gene therapy, etc.
– Strategies for tissue specific drug delivery to the kidney
– Key biomarkers and new technologies for predicting kidney damage and rate of disease progression
1-on-1 Meetings
Johnson & Johnson Innovation is inviting innovators with potential solutions for Chronic Kidney Disease to apply for the opportunity to be considered for a 1-on-1 meeting. Some of the key potential solutions we are looking for include:
– Reducing /stopping Albuminuria
– Repairing kidney structure and function
– Non-invasive quantification of Renal Fibrosis
– Identification of fast progressors of the disease
– New delivery technologies for kidney diseases
Additional areas of interest include unmet needs in:
– Acute kidney injury
– Autosomal dominant polycystic kidney disease
– Focal segmental glomerulosclerosis
– Nephrotic syndrome
– gA nephropathy
APPLY BY OCTOBER 8th: https://jnj-innovation.smapply.io/prog/1-on-1_meetings_jji_ckd/
SPEAKERS
– Jeremy Duffield, MD, PhD, FRCP | Chief Scientific Officer, Prime Medicine, Inc
– Maha Katabi | General Partner, Sofinnova Investments
– Matthew Breyer, MD | Distinguished Scientist, The Janssen Pharmaceutical Companies of Johnson & Johnson
– Maria Chiara Magnone | VP Kidney Diseases Research and Boston Site Head, Janssen Research and Development
AGENDA (Pacific Time Zone)
10:15 AM PT Welcome
10:20 AM PT Introductions
10:30 AM PT Panel Discussion
11:20 AM PT Audience Q & A
11:45 AM PT Closing Remarks
TICKETS
Complimentary. Registration closes on September 28th at 7:00 am PT.